United Therapeutics Q3 revenue rises 4%, beats estimates

Overview

• Rare disease therapy developer's Q3 revenue rose 4%, beating analyst expectations

• Net income fell 24% and diluted EPS declined 20% yr/yr

• Company repurchased nearly 1 mln shares in Q3, authorizing new $2 bln buyback in October

Outlook

• Company did not provide specific financial guidance for the current or future periods in its press release

Result Drivers

• TYVASO DPI SALES - Growth in Tyvaso DPI sales, driven by increased quantities sold and a price increase, contributed to higher total Tyvaso revenue

• COMPETITIVE PRESSURE - Co said availability of competing therapies negatively impacted sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin

• ORENITRAM SALES - Higher Orenitram revenue was driven by increased quantities sold and a price increase, partially offset by higher gross-to-net deductions

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for United Therapeutics Corporation is $690.00, about 14.7% above its November 3 closing price of $601.32

• The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 17 three months ago

Reuters Recommended Reads

• Nov 3 - Israel's Teva Q3 revenue falls 2% as generics decline

• Nov 3 - Madrigal Q3 Rezdiffra sales jump on strong demand, posts first profit

• Nov 3 - Strata Critical Medical Q3 revenue beats estimates; announces buyback

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)